Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 4/20 | 0.65 |
| ▸ | PLCG1 | P19174 | 4/20 | 0.62 |
| ▸ | PLCB3 | Q01970 | 4/20 | 0.62 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | APOB | P04114 | 9/20 | 0.40 |
| ▸ | MTTP | P55157 | 8/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17860468 | 1.00 | PAX8 (0.65) | PAX8PLCG1PLCB3CASP6MEN1 | |
| SCHEMBL16980367 | 1.00 | PAX8 (0.65) | PAX8PLCG1PLCB3CASP6MEN1 | |
| SCHEMBL17860402 | 0.97 | PAX8 (0.62) | PAX8PLCG1PLCB3CASP6MEN1 | |
| SCHEMBL16980396 | 0.95 | PAX8 (0.66) | PAX8PLCG1PLCB3CASP6MEN1 | |
| SCHEMBL17860300 | 0.94 | PAX8 (0.60) | PAX8PLCG1PLCB3CASP6APOB | |
| SCHEMBL17860362 | 0.94 | PAX8 (0.69) | PAX8PLCG1PLCB3CASP6 | |
| SCHEMBL17860371 | 0.93 | PAX8 (0.67) | PAX8PLCG1PLCB3CASP6 | |
| SCHEMBL17860363 | 0.92 | PAX8 (0.68) | PAX8PLCG1PLCB3CASP6MAPT | |
| SCHEMBL17860303 | 0.92 | PAX8 (0.55) | PAX8PLCG1PLCB3CASP6MEN1 | |
| SCHEMBL17860453 | 0.92 | PAX8 (0.73) | PAX8PLCG1PLCB3CASP6APOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526720-B2 | Modulators of hepatic lipoprotein metabolism | THE BROAD INSTITUTE, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| WO-2016100711-A1 | MODULATORS OF HEPATIC LIPOPROTEIN METABOLISM | THE BROAD INSTITUTE, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20150216855-A1 | Modulators of Hepatic Lipoprotein Metabolism | THE BROAD INSTITUTE, INC. | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216855-A1 | Modulators of Hepatic Lipoprotein Metabolism | CETP, LIPC, SLC10A1 | PAX8 4881/4885PLCG1 1203/4885PLCB3 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.